Nektar Therapeutics (NASDAQ: NKTR) stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin. Here’s what ...

Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia areata, even after the asset narrowly missed the main goal of a midstage ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) announced Tuesday that its investigational drug rezpegaldesleukin showed promising results in treating severe-to-very-severe alopecia areata in a ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A treatment for alopecia areata ...

The results will be provided in a morning press release and presented during the webcast. Interested participants can access the live webcast at this LINK. The event, the press release and the slides ...

Nektar Therapeutics (NKTR) has quietly transformed its performance over the past year, with the stock rising significantly from its multi year slump as investors revisit the company’s immunology ...

Fintel reports that on November 26, 2025, Citigroup initiated coverage of Nektar Therapeutics (NasdaqCM:NKTR) with a Buy recommendation. Analyst Price Forecast Suggests 58.63% Upside As of November 17 ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Nektar Therapeutics (NASDAQ:NKTR) reported Friday that Mark A. Wilson will step down as Chief Legal Officer, effective December 31, 2025. The company stated that Wilson’s departure is not the result ...

SAN FRANCISCO, Nov. 6, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2025. "We have made tremendous progress ...

Results of the Resolve-AD trial with rezpegaldesleukin were better than expected. In a nutshell, it looks like it could become a top-selling treatment for eczema, an itchy autoimmune disorder that ...